Ignyte Acquisition Corp (PKBO)
$0.02
$0.02
(666.67%)
As on 14-Nov-2024 15:00EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ignyte Acquisition Corp (PKBO)
| -87.8 | -- | 130.0 | -71.3 | -- | -- | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
Company
|
2023
|
|---|---|
|
Ignyte Acquisition Corp (PKBO)
| -95.5 |
|
BSE Sensex
| 18.7 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Ignyte Acquisition Corp (PKBO)
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with cancer, inflammatory, and rare diseases in the United States. The company's lead product candidate is PHP-303, which is... in Phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate in preclinical trials for solid tumors. Peak Bio, Inc. is based in Pleasanton, California. As of November 14, 2024, Peak Bio, Inc. operates as a subsidiary of Akari Therapeutics, Plc. Read more
-
Executive Chairman (Leave of Absence)
Dr. Hoyoung Huh M.D., Ph.D.
-
Executive Chairman (Leave of Absence)
Dr. Hoyoung Huh M.D., Ph.D.
-
Headquarters
Pleasanton, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ignyte Acquisition Corp (PKBO)
What is the current share price of Ignyte Acquisition Corp (PKBO) Today?
The share price of Ignyte Acquisition Corp (PKBO) is $0.02 (NASDAQ) as of 14-Nov-2024 15:00 EDT. Ignyte Acquisition Corp (PKBO) has given a return of -71.25% in the last 1 years.
What is the current PB & PE ratio of Ignyte Acquisition Corp (PKBO)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.34 |
-0.24 |
2022 |
-6.33 |
-10.24 |
2021 |
-- |
-- |
2020 |
-- |
-- |
2023 |
-0.34 |
-0.24 |
What is the 52 Week High and Low of Ignyte Acquisition Corp (PKBO)?
The 52-week high and low of Ignyte Acquisition Corp (PKBO) are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Ignyte Acquisition Corp (PKBO)?
Ignyte Acquisition Corp (PKBO) has a market capitalisation of $ 1 Mln as on 14-Nov-2024. As per SEBI classification, it is a company.
Should I invest in Ignyte Acquisition Corp (PKBO)?
Before investing in Ignyte Acquisition Corp (PKBO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.